tetano
Editor, Senior Moderator
Clin Infect Dis. 2015 Feb 18. pii: civ019. [Epub ahead of print]
[h=1]Clinical Effectiveness of Split-Virion Versus Subunit Trivalent Influenza Vaccines in Older Adults.[/h] Talbot HK[SUP]1[/SUP], Nian H[SUP]1[/SUP], Zhu Y[SUP]1[/SUP], Chen Q[SUP]1[/SUP], Williams JV[SUP]1[/SUP], Griffin MR[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses.
[h=4]METHODS:[/h] We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008-2009, 2010-2011, and 2011-2012 using a case-positive, control test-negative study design.
[h=4]RESULTS:[/h] Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infected patients were younger (P < .001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P < .001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P = .001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%-86.7%).
[h=4]CONCLUSIONS:[/h] Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] clinical effectiveness; influenza; older adults; split-virion vaccine; subunit vaccine
PMID: 25697739 [PubMed - as supplied by publisher]
[h=1]Clinical Effectiveness of Split-Virion Versus Subunit Trivalent Influenza Vaccines in Older Adults.[/h] Talbot HK[SUP]1[/SUP], Nian H[SUP]1[/SUP], Zhu Y[SUP]1[/SUP], Chen Q[SUP]1[/SUP], Williams JV[SUP]1[/SUP], Griffin MR[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses.
[h=4]METHODS:[/h] We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008-2009, 2010-2011, and 2011-2012 using a case-positive, control test-negative study design.
[h=4]RESULTS:[/h] Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infected patients were younger (P < .001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P < .001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P = .001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%-86.7%).
[h=4]CONCLUSIONS:[/h] Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] clinical effectiveness; influenza; older adults; split-virion vaccine; subunit vaccine
PMID: 25697739 [PubMed - as supplied by publisher]